New bone marrow model ‘big news’ for drug discovery
Scientists have created the first bioengineered bone marrow model which can support the type of human stem cells that are crucial for bone marrow transplants and in vitro study work.
The research – published in Nature Communications and led by the University of Glasgow – replicates key aspects of the human bone marrow microenvironment, to enable the support of rare long-term hematopoietic stem cells, or LT-HSCs.
LT-HSCs are vital for bone marrow transplants as they can replenish the blood cells after treatment for blood cancers. However, they are challenging to culture in the lab as they quickly change or die once out of the body.
This means that we rely on non-human, animal models to test drugs that can have effects on blood cell production and in targeting blood diseases (such as leukaemias).
This study, where LT-HSCs were cultured out of the body, in jelly-like gels, shows, for the first time that culturing the cells out of the body is possible.
The scientists demonstrate that gene editing of LT-HSCs in the gels is possible and believe the findings could provide a new way to test new drugs or techniques for treating blood disorders, such as sickle cell disease, and blood cancers, reducing the reliance on animal models, which are increasingly poor predictors of drug outcomes.
Testing human blood cells outside the body
Matt Dalby, Professor of Cell Engineering, and Director of Innovation, Engagement and Enterprise at the School of Molecular Biosciences at the University of Glasgow, said: “Our new research is incredibly exciting and is big news for the ability to effectively test new drugs. Currently used animal models are poor predictors of drug outcomes, and many of the blood disease treatments on offer – such as mRNA drugs and human-specific small molecules – don’t test well in animal models.
“By creating ambitious models of the bone marrow – which contain human cells and have the ability to mimic blood cell growth – we are thrilled to show for the first time that it is possible to test true human blood cells out with the human body, and the implications for accelerating therapies for diseases such as sickle cell disease and blood cancers gives us huge reason to be hopeful.”
Diana Spencer, Senior Digital Content Editor, DDW
